Shinichi Kageyama
Overview
Explore the profile of Shinichi Kageyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura K, Saito K, Higashi C, Kozuka Y, Yuasa H, Nishimura Y, et al.
Cancer Sci
. 2024 Dec;
116(3):744-752.
PMID: 39704015
Melanoma-associated antigen (MAGE)-A4, a cancer testis antigen, presents a promising target for chimeric antigen receptor T cell therapy in refractory solid tumors, including breast cancer (BC). However, the lack of...
2.
Kashima E, Sugimoto Y, Nagaharu K, Ohya E, Ikejiri M, Watanabe Y, et al.
Hematology
. 2024 Aug;
29(1):2392908.
PMID: 39163269
Chronic myelomonocytic leukemia is a clonal hematological disorder with an inherent risk of transformation to acute myeloid leukemia. Recently, there has been exponential discovery of molecular abnormalities in patients with...
3.
Asanuma K, Ishihara M, Nakamura T, Uchida K, Hagi T, Kageyama S, et al.
Anticancer Res
. 2023 Nov;
43(12):5737-5748.
PMID: 38030212
Background/aim: Cancer/testis antigens (CTAs) are well-known molecular targets with expression restricted to testicular germ cells and malignant tumors. T-cell receptor (TCR)-engineered T-cell (TCR-T) therapy against CTAs in patients with sarcoma...
4.
Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5069-5078.
PMID: 37792433
Purpose: To determine, for patients with advanced or recurrent synovial sarcoma (SS) not suitable for surgical resection and resistant to anthracycline, the safety and efficacy of the infusion of autologous...
5.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, et al.
Int J Cancer
. 2023 Feb;
152(12):2554-2566.
PMID: 36727538
The efficacy of immune checkpoint inhibitors is limited in refractory solid tumors. T-cell receptor gene-modified T (TCR-T)-cell therapy has attracted attention as a new immunotherapy for refractory cold tumors. We...
6.
Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, et al.
BMJ Open
. 2022 Nov;
12(11):e065109.
PMID: 36375974
Introduction: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development...
7.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35768164
Background: Because of the shortage of ideal cell surface antigens, the development of T-cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY-ESO-1 is a promising approach...
8.
Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, et al.
Cancer Immunol Immunother
. 2022 Apr;
71(11):2743-2755.
PMID: 35429246
The aim of this study was to determine the efficacy and the biomarkers of the CHP-NY-ESO-1 vaccine complexed with full-length NY-ESO-1 protein and a cholesteryl pullulan (CHP) in patients with...
9.
Kashima E, Nakano E, Watanabe Y, Imai H, Oka K, Kageyama S, et al.
Intern Med
. 2021 May;
60(22):3609-3614.
PMID: 34053988
Acute myeloid leukemia (AML) with BCR-ABL1, also termed Philadelphia chromosome-positive AML (Ph+ AML), is a rare leukemia subtype classified by the World Health Organization in 2016. The characteristics of Ph+...
10.
Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, et al.
Cancer Immunol Immunother
. 2021 Mar;
70(11):3081-3091.
PMID: 33751208
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8 and CD4 T cell...